Aerovate Therapeutics (AVTE) Insider Trading & Ownership $7.90 -0.18 (-2.23%) As of 08/29/2025 Add Compare Share Share Insider Trades Stock AnalysisChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Aerovate Therapeutics (NASDAQ:AVTE) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage24.90%Number OfInsiders Buying(Last 3 Years)0Number OfInsiders Selling(Last 3 Years)9Amount OfInsider Selling(Last 3 Years)$9.74M Get AVTE Insider Trade Alerts Want to know when executives and insiders are buying or selling Aerovate Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AVTE Insider Buying and Selling by Quarter Aerovate Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails6/14/2024George A EldridgeInsiderSell428$876.05$374,949.40 5/17/2024Hunter GilliesInsiderSell114$737.80$84,109.20 5/16/2024Timothy P. NoyesCEOSell285$755.30$215,260.50 5/2/2024Marinus VerwijsInsiderSell56$735.70$41,199.20 5/1/2024Timothy P. NoyesCEOSell324$711.90$230,655.60 4/17/2024Benjamin T DakeInsiderSell195$782.95$152,675.25 4/16/2024Timothy P. NoyesCEOSell285$864.50$246,382.50 4/10/2024George A EldridgeInsiderSell214$939.75$201,106.50 4/9/2024David S GrayzelDirectorSell339$985.25$333,999.75 4/1/2024Benjamin T DakeInsiderSell95$1,118.95$106,300.25 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 4/1/2024Timothy P. NoyesCEOSell285$1,050.00$299,250.00 3/27/2024Benjamin T DakeInsiderSell316$978.95$309,348.20 3/25/2024Benjamin T DakeInsiderSell98$980.35$96,074.30 3/19/2024Marinus VerwijsinsiderSell151$912.80$137,832.80 3/13/2024George A EldridgeInsiderSell57$875.70$49,914.90 3/11/2024George A EldridgeInsiderSell98$883.75$86,607.50 3/8/2024George A EldridgeInsiderSell3$875.00$2,625.00 2/23/2024Hunter GilliesInsiderSell14$682.50$9,555.00 2/20/2024Hunter GilliesInsiderSell99$708.05$70,096.95 2/5/2024Ralph NivenInsiderSell131$610.75$80,008.25 1/17/2024Hunter GilliesInsiderSell114$682.50$77,805.00 1/5/2024Ralph NivenInsiderSell131$670.60$87,848.60 12/27/2023Hunter GilliesInsiderSell3$857.50$2,572.50 12/20/2023Hunter GilliesInsiderSell114$682.50$77,805.00 12/13/2023Hunter GilliesInsiderSell60$682.50$40,950.00 12/5/2023Ralph NivenInsiderSell131$570.50$74,735.50 11/27/2023Benjamin T DakeInsiderSell357$568.40$202,918.80 11/24/2023Benjamin T DakeInsiderSell142$550.90$78,227.80 11/22/2023Benjamin T DakeInsiderSell268$530.95$142,294.60 11/1/2023Marinus VerwijsCTOSell27$366.10$9,884.70 11/1/2023Timothy P. NoyesCEOSell31$364.70$11,305.70 9/6/2023Benjamin T DakeInsiderSell112$527.10$59,035.20 8/7/2023Benjamin T DakeInsiderSell293$543.20$159,157.60 7/28/2023Timothy P. NoyesCEOSell156$630.00$98,280.00 7/17/2023Timothy P. NoyesCEOSell129$633.85$81,766.65 7/6/2023Benjamin T DakeInsiderSell293$583.10$170,848.30 7/3/2023Timothy P. NoyesCEOSell285$630.00$179,550.00 6/5/2023Ralph NivenInsiderSell64$569.10$36,422.40 5/19/2023Hunter GilliesInsiderSell1$682.50$682.50 5/17/2023Hunter GilliesInsiderSell31$685.65$21,255.15 The Robotics Revolution has arrived … and one $7 stock could take off as a result. (Ad)Something big is brewing in Washington. According to my research, an executive order from President Trump could be just weeks away. And it holds the potential to trigger one of the most explosive tech booms in US history. At the center of it all? Robots. Not the kind that clean your house or pour you coffee. But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year.This little-known company holds nearly 100 patents and trades for around $75/8/2023Benjamin T DakeInsiderSell293$763.00$223,559.00 5/5/2023Ralph NivenInsiderSell64$730.45$46,748.80 5/3/2023Marinus VerwijsSVPSell21$727.65$15,280.65 5/1/2023Timothy P NoyesCEOSell428$721.35$308,737.80 4/21/2023Hunter GilliesInsiderSell114$682.50$77,805.00 4/6/2023Benjamin T. DakeinsiderSell293$635.95$186,333.35 4/3/2023Timothy P. NoyesCEOSell428$678.65$290,462.20 3/6/2023Benjamin T. DakeinsiderSell293$830.55$243,351.15 3/1/2023Timothy P. NoyesCEOSell428$833.35$356,673.80 2/6/2023Benjamin T. DakeinsiderSell293$860.65$252,170.45 2/1/2023Timothy P. NoyesCEOSell428$793.80$339,746.40 1/6/2023Benjamin T. DakeinsiderSell293$909.30$266,424.90 1/3/2023Timothy P. NoyesCEOSell428$947.45$405,508.60 12/12/2022George A EldridgeInsiderSell285$1,051.40$299,649.00 12/8/2022George A EldridgeInsiderSell343$835.45$286,559.35 12/5/2022Ralph NivenInsiderSell64$608.30$38,931.20 12/1/2022Timothy P. NoyesCEOSell428$630.00$269,640.00 11/30/2022George A EldridgeInsiderSell2$667.10$1,334.20 11/23/2022George A EldridgeInsiderSell36$667.45$24,028.20 11/21/2022George A EldridgeInsiderSell0$665.00$0.00 11/18/2022George A EldridgeInsiderSell24$683.20$16,396.80 11/11/2022Benjamin T. DakeinsiderSell177$724.15$128,174.55 11/8/2022Benjamin T. DakeinsiderSell239$633.15$151,322.85 11/2/2022Marinus VerwijsSVPSell32$661.15$21,156.80 11/1/2022Timothy P. NoyesCEOSell29$682.50$19,792.50 10/17/2022Benjamin T. DakeinsiderSell119$705.60$83,966.40 10/14/2022Benjamin T. DakeinsiderSell3$701.75$2,105.25 10/10/2022Benjamin T. DakeinsiderSell141$591.15$83,352.15 10/7/2022Benjamin T. DakeinsiderSell300$560.35$168,105.00 10/5/2022Ralph NivenInsiderSell64$551.25$35,280.00 9/12/2022Benjamin T. DakeinsiderSell214$606.55$129,801.70 9/8/2022Benjamin T. DakeinsiderSell89$637.00$56,693.00 9/6/2022Benjamin T. DakeinsiderSell261$648.55$169,271.55 (Data available from 1/1/2013 forward) AVTE Insider Trading Activity - Frequently Asked Questions Who is on Aerovate Therapeutics' Insider Roster? The list of insiders at Aerovate Therapeutics includes Benjamin T Dake, David S Grayzel, George A Eldridge, Hunter Gillies, Marinus Verwijs, Ralph Niven, Timothy P Noyes. Learn more on insiders at AVTE. What percentage of Aerovate Therapeutics stock is owned by insiders? 24.90% of Aerovate Therapeutics stock is owned by insiders. Learn more on AVTE's insider holdings. Which Aerovate Therapeutics insiders have been selling company stock? The following insiders have sold AVTE shares in the last 24 months: Benjamin T Dake ($1,146,874.40), David S Grayzel ($333,999.75), George A Eldridge ($715,203.30), Hunter Gillies ($362,893.65), Marinus Verwijs ($188,916.70), Ralph Niven ($242,592.35), and Timothy P. Noyes ($1,002,854.30). How much insider selling is happening at Aerovate Therapeutics? Insiders have sold a total of 5,077 Aerovate Therapeutics shares in the last 24 months for a total of $3,993,334.45 sold. Aerovate Therapeutics Key ExecutivesMr. Timothy P. Noyes M.B.A. (Age 62)CEO & Director Compensation: $936.9kMr. George A. Eldridge (Age 61)CFO & Treasurer Compensation: $658.6kMr. Timothy J. Pigot (Age 53)Chief Commercial Officer Compensation: $584.6kDr. Benjamin T. Dake Ph.D. (Age 48)Founder, President, COO & Secretary Compensation: $435.5kDr. Marinus Verwijs Ph.D. (Age 48)Chief Technical Officer Compensation: $439.88kDr. Ralph W. Niven M.B.A. (Age 64)M.R, Ph.D., Pharm.S, Chief Scientific Officer Compensation: $372.33kMr. Hunter Gillies M.D. (Age 58)Chief Medical Officer Compensation: $512.74kMs. Donna DeaHead of Regulatory AffairsMs. Susan FischerExecutive Vice President of Development OperationsMr. Stephen K. YuSenior Vice President of Quality More Insider Trading Tools from MarketBeat Related Companies Trevi Therapeutics Insider Trading Urogen Pharma Insider Trading Phathom Pharmaceuticals Insider Trading Iovance Biotherapeutics Insider Trading Immunome Insider Trading uniQure Insider Trading Anavex Life Sciences Insider Trading Akebia Therapeutics Insider Trading Amylyx Pharmaceuticals Insider Trading Niagen Bioscience Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Costco Faces Downgrades, Death Cross, Insider SellingReynolds Consumer Products Stock Price: Insiders Signal a BottomBuy, Sell, or Hold? Insiders Pile Into These 3 Healthcare StocksInsiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift45 Stocks Insiders Are Selling That Analysts Say Buy This page (NASDAQ:AVTE) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerovate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
